SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (鈥淛unshi Biosciences鈥? HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (鈥淣MPA鈥? has accepted the supplemental new drug application (“sNDA鈥? for the company鈥檚 anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS 鈮 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (鈥淭NBC鈥?.